
    
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to
      evaluate the preliminary efficacy, safety, tolerability, and pharmacokinetics of topical R333
      ointment formulated at 6% (60 mg/g) in DLE and SLE patients with active discoid lesions.
    
  